Fatoş Dilan Köseoğlu

Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series

Background Renal impairment is a frequent and adverse prognostic factor in multiple myeloma (MM), with dialysis-dependent patients largely excluded from pivotal trials of B-cell maturation antigen (BCMA)-directed therapies. Elranatamab, a BCMA×CD3 bispecific antibody, has demonst...